Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Experimental cell therapy targets Hard-to-Treat cancers

NCT ID NCT05120271

First seen Jan 05, 2026 · Last updated May 20, 2026 · Updated 21 times

Summary

This early-stage trial tests a new treatment called BOXR1030, which uses specially engineered immune cells to attack cancer cells that have a protein called GPC3. The study includes adults with advanced liver, lung, skin, or soft-tissue cancers that have not responded to other treatments. Participants receive the cell therapy after chemotherapy to help the cells work better. The main goals are to check safety and find the best dose.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Baylor Scott and White Research Institute

    Dallas, Texas, 75246, United States

  • Beatson Institute for Cancer Research Wolfson Wohl Cancer Research Centre

    Glasgow, G61 1BD, United Kingdom

  • Fred Hutchinson Cancer Center - Seattle Cancer Care Alliance (SCCA) Location

    Seattle, Washington, 98109, United States

  • Froedtert and Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • Hoag Hospital Newport Beach

    Newport Beach, California, 92663, United States

  • The Royal Marsden NHS Foundation Trust

    London, SW3 6JJ, United Kingdom

  • University College London Hospitals NHS Foundation Trust

    London, NW1 2PG, United Kingdom

  • University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030-4008, United States

Conditions

Explore the condition pages connected to this study.